Acumen Pharmaceuticals (NASDAQ:ABOS) Releases Quarterly Earnings Results, Misses Expectations By $0.09 EPS

Acumen Pharmaceuticals (NASDAQ:ABOS) released its quarterly earnings data on Wednesday. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.09), FiscalAI reports.

Here are the key takeaways from Acumen Pharmaceuticals’ conference call:

• Acumen continues to expect top-line Phase II ALTITUDE-AD results in late 2026 for sabirnetug, including clinical efficacy, safety, ARIA rates, and fluid and imaging biomarker data.
• The company nominated two blood-brain-barrier delivery candidates, ACU301 and ACU401, with ACU401 showing up to 40-fold greater frontal-cortex exposure in non-human primates; Acumen expects to file an IND for a lead candidate in mid-2027.
• Management believes sabirnetug’s oligomer selectivity and IgG2 antibody design could provide a differentiated safety and tolerability profile versus plaque-targeting IgG1 therapies, though this remains to be demonstrated in the Phase II readout.
• Acumen ended the quarter with $110.2 million in cash and marketable securities, expected to fund operations only into early 2027, while reporting a second-quarter net loss of $32.7 million.

Acumen Pharmaceuticals Stock Performance

Shares of NASDAQ:ABOS traded up $0.08 during midday trading on Wednesday, reaching $2.55. 299,608 shares of the company traded hands, compared to its average volume of 594,859. The firm’s fifty day moving average price is $2.36 and its two-hundred day moving average price is $2.54. Acumen Pharmaceuticals has a 12 month low of $1.21 and a 12 month high of $3.60. The firm has a market capitalization of $184.19 million, a price-to-earnings ratio of -1.37 and a beta of 0.36. The company has a quick ratio of 4.55, a current ratio of 4.55 and a debt-to-equity ratio of 0.19.

Insider Transactions at Acumen Pharmaceuticals

In other news, Director Derrell Porter sold 13,040 shares of the business’s stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $2.33, for a total transaction of $30,383.20. Following the completion of the transaction, the director directly owned 35,500 shares in the company, valued at $82,715. The trade was a 26.86% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In the last 90 days, insiders have sold 38,700 shares of company stock valued at $89,660. Corporate insiders own 10.20% of the company’s stock.

Hedge Funds Weigh In On Acumen Pharmaceuticals

A number of large investors have recently bought and sold shares of ABOS. Jacobs Levy Equity Management Inc. bought a new stake in shares of Acumen Pharmaceuticals during the 3rd quarter valued at about $27,000. Marshall Wace LLP bought a new position in shares of Acumen Pharmaceuticals during the fourth quarter valued at $44,000. OMERS ADMINISTRATION Corp purchased a new stake in shares of Acumen Pharmaceuticals during the fourth quarter valued at approximately $47,000. Marex Group plc bought a new position in Acumen Pharmaceuticals in the 2nd quarter valued at approximately $39,000. Finally, AQR Capital Management LLC purchased a new stake in shares of Acumen Pharmaceuticals during the first quarter valued at $46,000. 71.01% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have recently issued reports on ABOS. Wall Street Zen downgraded Acumen Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday, July 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Acumen Pharmaceuticals in a research note on Monday, July 6th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Acumen Pharmaceuticals currently has an average rating of “Hold” and an average target price of $8.00.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral small molecule therapies for neurodegenerative diseases. Leveraging a proprietary drug discovery platform that integrates chemoproteomics, high-throughput screening and computational chemistry, the company seeks to identify and optimize compounds that selectively modulate pathological protein aggregation. Its approach is designed to address the underlying biology of conditions such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis and related proteinopathies.

The company’s pipeline comprises multiple lead candidates at various stages of preclinical and early clinical development.